A new report by the Deloitte Center for Health Solutions finds significant opportunities for the adoption of personalized medicine to produce a positive return on investment for key stakeholders in the U.S. healthcare system. The report also finds that consumers stand to gain the most significant ROI within the shortest time period.
The report, titled “The ROI for Targeted Therapies: A Strategic Perspective,” provides an analysis of personalized medicine’s economic value proposition. It examines the importance of ROI for multiple stakeholders--consumers, diagnostic companies, pharmaceutical and biotechnology companies, and payers. A literature review of two clinical scenarios found that all stakeholder groups experienced a positive ROI under certain conditions, and that consumers consistently experienced a positive ROI across all scenarios. Payers received only a marginal benefit, and that was after six years.
The report also concludes that providers could benefit from the new tools offered by personalized medicine to improve patient care; however, reimbursement issues will need to be worked out with payers. Additionally, as providers implement electronic health records, new decision-support tools will help facilitate the adoption of disease-specific standards of practice that can provide real-time data to help prioritize therapies based on potential drug interactions and patient clinical profiles.
Read the report.
